Novo Nordisk registers real-world cardiometabolic study using Turkish EHR data
SCALA-TK-CM will analyze health records from Turkey's Acibadem hospital network to map cardiometabolic disease patterns.
This week's update covers one newly registered observational study from Novo Nordisk.
- Novo Nordisk registered "SCALA-TK-CM," a retrospective observational cohort study (NCT07781371) that is designed to determine the prevalence and overlap of major cardiometabolic diseases, identify multimorbidity clusters, and characterize demographic, clinical, laboratory, and treatment patterns across the cohort and relevant subgroups.1 The study is based on anonymized electronic health record data spanning January 2022 to December 2025, extracted from participants of the Acibadem hospital network in Turkey.1 It is estimated to enroll 100000 participants1 and covers conditions including Obesity, Type 2 Diabetes, Prediabetes, Cardiovascular Disease, Dyslipidemia, Metabolic Dysfunction-associated Steatotic Liver Disease, and Chronic Kidney Disease.1 The study status is not yet recruiting, with an estimated start date of 2026-08-20.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.